dea cannabis scheduling delay
Stop Blaming The DEA For Cannabis Stock Chaos
In 2024, the DEA’s scheduling review contributed only a 5% dip in cannabis stock values, while the real driver is the FDA’s stalled CBD framework. The agency’s inability to issue clear guidelines for hemp oil and other CBD products has created a procedural limbo that investors mistake